Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philipp Rassek

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Nuklearmedizin. Nuclear Medicine|August 18, 2023
[18F]-PSMA-1007-PET for evaluation of kidney functionPhilipp Rassek, Michael Schäfers, Kambiz Rahbar, et al.
Cancers|August 12, 2023
Diffusion-Weighted MRI for Treatment Response Assessment in Osteoblastic Metastases-A Repeatability StudyMaria Eveslage, Philipp Rassek, Arne Riegel, et al.
Nuklearmedizin. Nuclear Medicine|July 12, 2024
Determination of the optimal imaging protocol for [18F]PSMA-PET-CT for the detection of bone metastases in prostate cancer patientsLinus Bredensteiner, David Ventura, Philipp Rassek, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|September 19, 2024
Early treatment response assessment with [<sup>177</sup>Lu]PSMA whole-body-scintigraphy compared to interim PSMA-PETDavid Ventura, Philipp Rassek, Philipp Schindler, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 27, 2022
Safety and Survival Outcomes of <sup>177</sup>Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior <sup>223</sup>Ra treatment: The RALU StudyKambiz Rahbar, Markus Essler, Kim M Pabst, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 12, 2023
<sup>177</sup>Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior <sup>223</sup>Ra (RALU Study)Kambiz Rahbar, Markus Essler, Matthias Eiber, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Nuklearmedizin. Nuclear Medicine|August 18, 2023
[18F]-PSMA-1007-PET for evaluation of kidney functionPhilipp Rassek, Michael Schäfers, Kambiz Rahbar, et al.
Cancers|August 12, 2023
Diffusion-Weighted MRI for Treatment Response Assessment in Osteoblastic Metastases-A Repeatability StudyMaria Eveslage, Philipp Rassek, Arne Riegel, et al.
Nuklearmedizin. Nuclear Medicine|July 12, 2024
Determination of the optimal imaging protocol for [18F]PSMA-PET-CT for the detection of bone metastases in prostate cancer patientsLinus Bredensteiner, David Ventura, Philipp Rassek, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|September 19, 2024
Early treatment response assessment with [<sup>177</sup>Lu]PSMA whole-body-scintigraphy compared to interim PSMA-PETDavid Ventura, Philipp Rassek, Philipp Schindler, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 27, 2022
Safety and Survival Outcomes of <sup>177</sup>Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior <sup>223</sup>Ra treatment: The RALU StudyKambiz Rahbar, Markus Essler, Kim M Pabst, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 12, 2023
<sup>177</sup>Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior <sup>223</sup>Ra (RALU Study)Kambiz Rahbar, Markus Essler, Matthias Eiber, et al.
Pageof 1